All In Biotech

Drug Trial Radar · NCT06612775

A Study to Evaluate the Safety, Tolerability, and Efficacy of CB03-154 in Adult Patients With Focal Epilepsy

A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Safety, Tolerability, and Efficacy of CB03-154 as Adjunctive Therapy in Focal Epilepsy

Last checked: Nov 19, 2026Latest source record: Sep 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 180 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

180

Planned (sponsor's estimate)

Start

Aug 14, 2024

Primary completion

Sep 2027

Study completion Nov 2027

Sponsor

Sponsor type
Industry
First posted
Sep 25, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

CB03-154 is an investigational drug developed by Shanghai Zhimeng Biopharma Inc. for the treatment of Focal Epilepsy.

Conditions

  • Focal Epilepsy

Interventions

  • Test drug CB03-154 5mg groupDrug

    CB03-154 tablet (5mg/tablet) once daily.

  • Test drug CB03-154 10mg groupDrug

    Two CB03-154 tablets (5mg/tablet) once daily.

  • Test drug CB03-154 20mg groupDrug

    Four CB03-154 tablets (5mg/tablet) once daily.

  • Placebo groupDrug

    Four Placebo tablets once daily.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To assess the efficacy of CB03-154 compared to placebo on focal seizure frequency in adults with focal epilepsy taking 1 to 3 AEDs in the double-blind period (DBP).Time frame: From baseline to the entire period of double-blind period, assessed up to 20 weeks.
  2. To assess the safety and tolerability by evaluating the frequency and severity of adverse events (AEs) /serious adverse events (SAEs) of CB03-154 in adults with focal epilepsy taking 1 to 3 AEDs in the DBP.Time frame: From the entire period of double-blind period of 12 weeks to the post-treatment follow-up period of 2 weeks(+7 days), assessed up to 17 weeks.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Alfred Health

    Melbourne, Victoria, Australia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.